In spinning out cancer pipeline, Alkermes cites Inflation Reduction Act's hypothetical incentives for biologics R&D
Alkermes announced Wednesday morning it would siphon off its burgeoning oncology business, and cited one of President Joe Biden’s signature pieces of legislation as a motivator.
The Irish biotech decided to spin out its cancer pipeline in order to capitalize on biologics research, execs said Wednesday, following Biden’s signing of the Inflation Reduction Act into law. With the comments, Alkermes became the third biopharma company in the last week to cite the IRA in its business and R&D decisions, following Alnylam and Eli Lilly.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,800+ biopharma pros reading Endpoints daily — and it's free.